Drugs That Require Eye Exam
From Anvita Health Wiki
Contents |
Introduction
- Includes:
-
-
- occur in ~70% of patients on amiodarone
- may result in vision loss
- optic neuritis
- optic neuropathy
- optic neuropathy &/or neuritis may occur any time after starting amiodarone (2% of patients on amiodarone) visual impairment & blindness can result
- photosensitivity
- patients taking amiodarone should have a baseline eye exam & eye exams every 6-12 months
- patients should call provider if visual disturbances
- chloroquine ( Aralen), hydroxychloroquine ( Plaquenil)
- blurred vision
- contact lens intolerance
- corneal deposits
- retinopathy
- dose-related, occurs with long-term therapy
- retinal changes & visual disturbances may progress after drug is stopped
- baseline & eye exams every 3-6 months
- discontinue for any visual disturbances
- ethambutol ( Myambutol, Etibi)
-
- may be related to dose and duration of treatment
- generally reversible when ethambutol is stopped
- may continue to progress for 1-2 months after discontinuation
- recovery may be delayed for > 1 year
- irreversible blindness has been reported
- visual field defects
- eye exams at baseline & periodically thereafter
- patients on > 15 mg/kg/day should have monthly eye exams
- notify provider of any vision changes
-
- dose-related & resolve in a couple of months after therapy is stopped
- decreased night vision may persist after therapy is stopped
- pseudotumor cerebri ( intracranial hypertension)
- papilledema
- photophobia
- reduced tolerance to contact lenses
- visual changes are dose related
- stop retinoid if any visual difficulties or headaches, with eye exam to rule out papilledema secondary to intracranial hypertension
- periodic eye exams if oral retinoid therapy for >= 6 months
-
- decreased vision & color vision, visual field defects
- reported cases occurred after 5-11 months of therapy
- symptoms improve after discontinuation
- eye exam if treatment for >= 3 months
- vigabatrin ( Sabril)-Canada only
- optic atrophy
- optic neuritis
- peripheral constriction of visual field
- occurs in ~ 30% of patients
- usually occurs in the first 4 years of treatment
- mechanism may be retinal toxicity from elevated levels of GABA
- visual field defects are likely permanent even after stopping vigabatrin
- visual field examinations before or soon after starting vigabatrin are recommended, then every 3 months thereafter
- optic neuritis
- papilledema
- ocular adverse effects have occurred mainly in severely ill patients
- if administration > 28 days, visual function should be monitored
-
More General Terms
Additional Terms
References
- Prescriber's Letter 16(1): 2009 Drug-Induced Ocular Effects Detail-Document#: [1] (subscription needed) [2]
